Update on clopidogrel and dual anti-platelet therapy: neurology
|
|
- Silvester Doyle
- 6 years ago
- Views:
Transcription
1 European Heart Journal Supplements (2006) 8 (Supplement G), G15 G19 doi: /eurheartj/sul049 Update on clopidogrel and dual anti-platelet therapy: neurology Hans-Christoph Diener Department of Neurology, University Duisburg-Essen, Hufelandstrasse 55, Essen, Germany KEYWORDS Stroke; Secondary prevention; Clopidogrel; Acetylsalicylic acid; Combination therapy; Bleeding complications Patients suffering a transient ischaemic attack (TIA) or ischaemic stroke (IS) have a high recurrence risk. The inhibition of platelet function is effective in the reduction of secondary vascular events in patients with TIA or stroke. This is true for acetylsalicylic acid (ASA), clopidogrel, ticlopidine, and the combination of ASA and slowrelease dipyridamole. This review analyses the results of recent trials like clopidogrel as well as the combination of clopidogrel plus ASA. Clopidogrel is superior to ASA in the prevention of vascular events in patients with IS, myocardial infarction, or peripheral arterial disease. The difference is highest for high-risk patients such as diabetics, patients who underwent coronary bypass surgery, and patients with additional vascular events. A prediction model which allows to identify patients in whom clopidogrel is superior to ASA for the secondary prevention of stroke is presented. In high-risk patients with TIA or stroke, the combination of clopidogrel plus ASA is not superior to clopidogrel monotherapy, but results in a higher rate of bleeding complications. Combination therapy is superior to aspirin monotherapy for the prevention of strokes but not for a combined vascular endpoint. Introduction Stroke Patients at risk of ischaemic events Atherosclerosis is a chronic, disseminated process that causes structural changes in the intima and media of large and medium-sized arteries, initially resulting in endothelial abnormalities and eventually producing atherosclerotic plaques. Thrombosis, as the main complication of atherosclerosis, is mainly caused by platelet activation and aggregation arising from disruption of an atherosclerotic plaque. Atherothrombosis leads to local occlusion or distal embolism, the three common clinical manifestations being coronary heart disease [myocardial infarction (MI) and angina pectoris (AP)], peripheral arterial disease (PAD), and cerebrovascular events such as transient ischaemic attacks (TIA) and ischaemic stroke (IS). Corresponding author. address: h.diener@uni-essen.de Acute stroke is increasingly recognized as one of the leading factors of morbidity and mortality worldwide. Its economical burden is among the highest of all diseases. Over the past decades, acute stroke has increasingly being recognized as a medical emergency. Acute, post-acute, and rehabilitation care of stroke patients in specialized wards as well as revascularizing therapies have been shown to be effective in acute IS. IS accounts for 85% of all strokes, whereas the remaining 15% are due to cerebral haemorrhage. Large vessel atherothrombosis, cardiac embolism, and small vessel occlusion each account for around 20% of all strokes, whereas the aetiology is undetermined in 15% and the remaining 5% are due to other defined causes. 1 Especially, in middle-aged men (45 70 years), large vessel disease is a predominant aetiology. Besides a higher risk of recurrent cerebral events, stroke patients are also at high risk of developing cardiac events. 2 & The European Society of Cardiology All rights reserved. For Permissions, please journals.permissions@oxfordjournals.org
2 G16 H.-C. Diener Secondary prevention of stroke with anti-platelet drugs Recurrence risk after TIA or IS ranges from 5 to 20% per year. 1,3,4 The risk is highest immediately after the first event. 5 8 Numerous trials and meta-analyses have left little doubt that anti-platelet therapy effectively reduces stroke risk in patients with prior IS or TIA The latest publication from the Antithrombotic Trialists s Collaboration 9 involves the meta-analysis of 287 trials with patients in comparisons of antiplatelet therapy vs. controls, and in comparisons of different anti-platelet regimens. The main results were summarized as a reduction of serious vascular events [which includes non-fatal MI, non-fatal stroke, or vascular death (VD)] by about 25% (relative percentage). In absolute terms, the events prevented include 3.6% treated for 2 years among those with previous IS or TIA. The absolute benefits substantially outweigh the absolute risks of major extracranial bleeding. Nevertheless, controversies exist. Foremost among them is the debate over the optimal anti-platelet regimen. The majority of research in secondary stroke prevention supports the clinical value of acetylsalicylic acid (ASA). Several key questions, however, remain unanswered. Is the routine use of anti-platelet therapy justified for all eligible patients? Should ASA be used alone or in combination with another anti-platelet agent such as clopidogrel with a different mode of action? Will administration of low-dose ASA reduce the incidence of side effects? Are the new anti-platelet drugs like clopidogrel superior to ASA? This article is an updated version of an earlier review 13 and summarizes the results of recent clinical trials performed with clopidogrel in the context of evolving strategies for stroke prevention. Clinical efficacy Clopidogrel for the prevention of vascular events in patients with IS, MI, or PAD (CAPRIE) The CAPRIE study was the largest study to date that has tested clopidogrel in the setting of stroke patients. 14 It was a randomized, double-blind study, which compared the effects of 75 mg of clopidogrel with 325 mg of ASA once daily. The aim was to reduce a composite endpoint, which consisted of either IS, MI, or VD. A total of patients with a previous MI or IS, or established PAD were randomized. TIA patients were not included into the CAPRIE-trial. After a mean follow-up period of 1.9 years there was a significant absolute risk reduction of 0.5% and a relative risk reduction (RRR) of 8.7% in favour of clopidogrel. Thus, clopidogrel is slightly more effective than ASA in preventing a composite endpoint of vascular events. It is the agent of choice in patients with contraindications to, or adverse effects on, ASA. For the subgroup of patients in the CAPRIE trial with IS (n ¼ 6431) as the qualifying event, the RRR was 7.3% and not statistically significant (95% CI 25.7 to 18.7). However, the CAPRIE study was not designed to specifically address this subgroup of patients. In several post hoc analyses of the CAPRIE trial, the benefit of clopidogrel was demonstrated to be amplified among high-risk subgroups, including patients with a history of previous IS or MI, 15 patients with diabetes, 16 those with prior cardiac surgery, 17 and those receiving lipid-lowering therapy. 18 In the 4496 patients with a history of previous IS or MI before their qualifying event, clopidogrel produced an RRR of 14.9% vs. ASA for the primary CAPRIE endpoint (P ¼ 0.045). 15 This risk reduction translates into a number of patients needed to treat (NNT) of 71 per year with clopidogrel instead of ASA to prevent further vascular events. For comparison, the NNT is 200 patients per year for the overall CAPRIE population. CARESS trial The CARESS trial, in which the combined use of clopidogrel and ASA was significantly more effective than ASA alone in reducing cerebral microemboli measured by transcranial Doppler sonography in patients with recently symptomatic moderate-to-severe carotid stenosis, identified a subgroup of patients in whom combination therapy might be superior to monotherapy with ASA. 19 The number of patients, 110, was too small to reach a significant reduction in clinical endpoints. Numerically, the number of strokes was smaller in the combination group (0 vs. 4). In CARESS, patients received either a loading dose of 300 mg clopidogrel followed by 75 mg for 7 days plus aspirin or aspirin monotherapy. MATCH trial The MATCH (Management of ATherothrombosis with Clopidogrel in High-risk patients with recent TIA or IS) trial was a randomized, double-blind, placebo-controlled trial that compared ASA (75 mg/day) vs. placebo in 7599 high-risk patients with recent TIA or IS and at least one additional vascular risk factor in patients receiving clopidogrel 75 mg/day. 20,21 Additional vascular risk factors were defined as previous IS, previous MI, angina pectoris, diabetes mellitus, or symptomatic PAD within the previous 3 years. The duration of treatment and follow-up was 18 months. The primary endpoint was a composite of IS, MI, VD, or rehospitalization for acute ischaemia (including rehospitalization for TIA, angina pectoris, or worsening of PAD). Five hundred and ninety-six (15.7%) patients reached the primary endpoint in the group receiving ASA plus clopidogrel compared with 636 (16.7%) patients in the clopidogrel alone group [RRR 6.4%, 95% CI 24.6, 16.3; absolute risk reduction 1% (95% CI 20.6, 2.7); Figure 1]. Life-threatening bleedings were significantly higher in the group receiving ASA plus clopidogrel [96 (2.6%) vs. clopidogrel alone 49 (1.3%); (absolute risk increase 1.3%) 95% CI 0.6, 1.9)]. Major bleedings were also increased in the group receiving ASA in addition to clopidogrel but there was no difference in mortality. Adding ASA to clopidogrel in high-risk patients with recent IS or TIA is associated with a
3 Update on clopidogrel and dual anti-platelet therapy G17 Table 1 Stroke prediction model based on the stroke subgroup in the CAPRIE trial Risk factors Points,65 years years 1.75 years 2 Hypertension (Yes) 1 Diabetes (Yes) 1 Previous MI 1 Other cardiovascular disease (except MI and AF) 1 PAD 1 Smoker (Yes) 1 Additional TIA or IS in addition to qualifying event 1 Figure 1 Patients remaining event-free over time for the primary endpoint (MI, IS, CVD, or rehospitalization due to ischaemic event) in the MATCH trial; intention-to treat population. non-significant difference in terms of major vascular events. However, the risk of life-threatening and major bleeding is increased by the addition of ASA. Predefined subgroup analyses were unable to identify a group of patients were the benefit of combination therapy would outweigh the bleeding risk. The benefit of the combination therapy was highest in patients randomized early after the qualifying event, whereas the differences in bleeding complications emerged only after 3 months. Theoretically, this would indicate that there is a window of opportunity for short-term use of the combination. This, however has to be investigated in a separate trial (FASTER, see below). CHARISMA study The CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance) study, which has recruited patients investigated the role of clopidogrel in both primary and secondary prevention. 22,23 The target study population was one at high risk of atherothrombotic events subjects have documented cerebrovascular, cardiovascular, or PAD. However, subjects with vascular risk factors without a documented event were also enrolled (primary prevention). CHARISMA compared the combination of clopidogrel plus ASA with ASA plus placebo. The rate of the primary efficacy endpoint (composite of MI, IS, or death from cardiovascular causes) showed a RRR of 7% in favour of the combination therapy. 24 This difference was not significant. The only secondary endpoint which showed a significant benefit of combination over monotherapy was non-fatal stroke (150/189 strokes). The results for the patients with stroke as a qualifying event are not yet published. Figure 2 Annual event rate for IS (%) in the MATCH trial gained from the IS population according to the risk score (see Table 1). Please note that the risk scores of 7 and 8 are based on small patient numbers and have wide confidence intervals. Risk model to identify patients at high risk for stroke recurrence Based on a subgroup analysis of the stroke cohort in the CAPRIE trial 15 and the risk factors identified by logistic regression analysis, we developed a predictive model. 13 As shown in Table 1, we assigned points to certain baseline variables and risk factors. The maximal possible score is 10. Rates for recurrent strokes were calculated for each risk factor group separately for ASA and clopidogrel. Overall, the patient population can be separated at an annual stroke risk of smaller or grater than 4% into a low- and a high-risk group. As can be seen from Figure 2, in the low-risk group, there is no difference between ASA and clopidogrel. In the high-risk group (3 6 points), clopidogrel is superior to ASA. The very high-risk group (.6 points) contains few patients and the results have wide confidence intervals. These results clearly favour a strategy in which the stroke recurrence risk guides the decision to use either ASA or clopidogrel for secondary stroke prevention. Ongoing trials The Fast Assessment of Stroke and TIA to prevent Early Recurrence trial (FASTER) will focus on clopidogrel and
4 G18 H.-C. Diener Table 2 Ongoing and planned clinical trials of anti-platelet therapy in stroke prevention [after (Hankey, 2004 #1)] Trial Patients Onset Interventions Primary endpoint Sample size ARCH TIA or IS and aortic arch plaque (14 mm) 0 6 months Clopidogrel 75 mg þ ASA mg vs. warfarin ACTIVE AF (high-risk) Clopidogrel þ ASA vs. warfarin Clopidogrel þ ASA vs. ASA Irbesartan vs. Placebo FASTER TIA or minor IS, Treatment within 12 h after symptom onset 0 12 h Clopidogrel 300 mg loading dose, 75 mg/day vs. placebo. ASA for all patients. Simvastatin 40 mg vs. placebo ProFESS IS 0 90 days Clopidogrel vs. Dipyridamole þ ASA; Telmisartan vs. Placebo SPS3 Small subcortical stroke (MRI) MMSE months Clopidogrel vs. Placebo ASA for all patients IS, MI, VD, or emboli IS, MI, VD (þ emboli for the comparisons between Clopidogrel þ ASA vs. ASA and between Clopidogrel þ ASA vs. warfarin) Stroke at 90 days, combined outcome of myocardial infarction, stroke, or VD at 90 days, stroke severity First recurrent stroke Stroke ASA in the setting of TIA. In this trial, a loading dose of 300 mg clopidogrel is used. A secondary consideration is whether simvastatin is superior to placebo. The primary endpoint is the 90-day risk of stroke. Inclusion time 12 h after a TIA is short. Therefore, FASTER will focus on early secondary prevention (Table 2). The SPS3 (Secondary Prevention of Small Subcortical Strokes) trial investigates not only whether recurrent stroke can be avoided but also whether dementia a high risk in this population can be prevented. Around 2500 patients with small subcortical strokes will be included; those with cardioembolic, cortical or haemorrhagic stroke are excluded. The trial has two treatment arms. In the anti-platelet study, patients will be randomized to ASA and placebo or ASA and clopidogrel. The other treatment arm investigates moderate vs. aggressive blood pressure control. The ongoing PROFESS trial will recruit patients with IS and compare 75 mg clopidogrel with the combination of low-dose ASA with slow-release dipyridamole. This trial is supposed to identify subgroups of patients who might benefit more from one treatment regimen than the other based on risk factors and concomitant diseases. Conclusions Clopidogrel is effective in the prevention of vascular events in high-risk patients and, as shown in subgroup analyses of CAPRIE, this is especially true for people with PAD or diabetes mellitus. A stroke recurrence prediction model offers guidance on which patients should receive ASA or clopidogrel for secondary stroke prevention. Clopidogrel has fewer gastrointestinal side-effects than ASA. However, it does not demonstrate difference from ASA in patients with IS overall. Presently, the combination of clopidogrel plus ASA cannot be recommended in high-risk patients with TIA or IS. In this group, the combination is not superior to clopidogrel or aspirin monotherapy but leads to more bleeding complications. In the future, trials may show that the combination of clopidogrel plus ASA is superior to ASA or clopidogrel alone in the secondary prevention of stroke in high-risk patients, vascular events after TIA, lacunar stroke, and vascular dementia. However, this higher efficacy may come at the price of a higher bleeding rate. The results of ongoing trials, including PROFESS, will help us assess this risk benefit ratio accurately. Acknowledgements Financial support for research projects was provided by Astra/ Zeneca, GSK, Böhringer Ingelheim, Novartis, Janssen-Cilag, sanofi-aventis. The Department of Neurology at the University, Duisburg-Essen received research grants from the German Research Council (DFG), the German Ministry of Education and Research (BMBF), the European Union, the Bertelsmann Foundation, and the Heinz-Nixdorf Foundation. Conflict of interest: H.-C.D. received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Abbott, AstraZeneca, Bayer Vital, Böhringer Ingelheim, D-Pharm, Fresenius, GlaxoSmithKline, Janssen Cilag, MSD, Novartis, Novo-Nordisk, Paion, Parke-Davis, Pfizer, sanofiaventis, Sankyo, Servier, Solvay, Wyeth, Yamaguchi. References 1. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, Glahn J, Brandt T, Hacke W, Diener H. Risk factors, outcome, and treatment in subtypes of ischaemic stroke: the German stroke data bank. Stroke 2001;32:
5 Update on clopidogrel and dual anti-platelet therapy G19 2. Hankey GJ. Stroke. How large a public health problem, and how can the neurologist help? Arch Neurol 1999;56: Wilterdink JL, Easton JD. Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992;49: Weimar C, Kraywinkel K, Rodl J, Hippe A, Harms L, Kloth A, Diener HC, German Stroke Data Bank Collaborators. Etiology, duration, and prognosis of transient ischaemic attacks: an analysis from the German Stroke Data Bank. Arch Neurol 2002;59: Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000;284: Weimar C, Roth MP, Zillessen G, Glahn J, Wimmer ML, Busse O, Haberl RL, Diener HC. German Stroke Data Bank Collaborators. Complications following acute ischaemic stroke. Eur Neurol 2002;48: Lovett J, Coull A, Rothwell P. Early risk of recurrence by subtype of ischaemic stroke in population-based incidence studies. Neurology 2004;62: Rothwell PM, Warlow CP. Timing of TIAs preceding stroke: time window for prevention is very short. Neurology 2005;64: Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002;524: Antiplatelet Trialists Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994;308: Antiplatelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988;296: Patrono C, Roth GJ. Aspirin in ischaemic cerebrovascular disease. Stroke 1996;27: Diener HC, Ringleb PA, Savi P. Clopidogrel for secondary prevention of stroke. Expert Opin Pharmacother 2005;6: CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348: Ringleb P, Bhatt D, Hirsch A, Topol E, Hacke W. Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events Investigators. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischaemic events. Stroke 2004;35: Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002;90: Bhatt D, Chew D, Hirsch A, Ringleb P, Hacke W, Topol E. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001;103: Bhatt D, Foody J, Hirsch A, Ringleb P, Hacke W, Topol E. Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherothrombosis. J Am Coll Cardiol 2000;35(Suppl. A): Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, Ringelstein EB. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using Doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111: Diener H, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H-J, on behalf of the MATCH Investigators. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data. Cererbrovasc Dis 2004;17: Diener H, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht H-J, on behalf of the MATCH Investigators. Acetylsalicylic acid on a background of clopidogrel in high-risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results. Lancet 2004;364: Bhatt DL, Topol EJ; on behalf of the CHARISMA Executive Committee. Clopidogrel added to aspirin alone in secondary prevention and highrisk primary prevention. Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004;148: Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ. A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2005;150: Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Brennan DM, Fabry-Ribaudo L, Booth J, Topol EJ, for the CHARISMA trial. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:
Prevention of Vascular Events in Patients with Cerebrovascular Disease: Efficacy and Appropriate Duration of Antiplatelet Therapy
Clin. Cardiol. 29, 244 248 (2006) Prevention of Vascular Events in Patients with Cerebrovascular Disease: Efficacy and Appropriate Duration of Antiplatelet Therapy GABRIEL B. HABIB, SR., M.D., M.S., FACC,
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationThe secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy,
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. LEASURE, MD Results of the Management of Atherothrombosis With Clopidogrel in High-Risk atients Trial Implications for the Neurologist Marc Fisher, MD The secondary
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationNew Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More informationModified-release dipyridamole combined with aspirin for secondary stroke prevention
For reprint orders, please contact: reprints@futuremedicine.com DRUG EVALUATION Modified-release dipyridamole combined with aspirin for secondary stroke prevention Hans-Christoph Diener University Essen,
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationPatients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
Journal of the American College of Cardiology Vol. 49, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.03.025
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationAntithrombotic management options for acute ischemic large-vessel stroke: A meta-analysis of randomized clinical trials
Antithrombotic management options for acute ischemic large-vessel stroke: A meta-analysis of randomized clinical trials Background Stroke affects one in every 20 individuals in developed countries and
More information44TH ANNUAL RECENT ADVANCES IN NEUROLOGY
Presenter Disclosure Information J. Donald Easton, MD Clinical Professor of Neurology February 17, 2011 44TH ANNUAL RECENT ADVANCES IN NEUROLOGY TIA: Definition, Evaluation, and Treatment J. Donald Easton,
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More information5/2/2016. Outpatient Stroke Management Sheila Smith MD May 5, 2016
Outpatient Stroke Management Sheila Smith MD May 5, 2016 1 Management of Outpatient Stroke Objectives Review blood pressure management post stroke Review antithrombotic therapy Review statin therapy Discuss
More informationYingying Yang, 1,2,3,4 Mengyuan Zhou, 1,2,4,3 Xi Zhong, 1,2,4,3 Yongjun Wang, 1,2,4,3 Xingquan Zhao, 1,2,4,3 Liping Liu, 1,2,4,3 Yilong Wang 1,2,4,3
To cite: Yang Y, Zhou M, Zhong X, et al. Dual versus mono antiplatelet therapy for acute non-cardioembolic ischaemic stroke or transient ischaemic attack: a systematic review and meta-analysis. Stroke
More informationAnti-platelet therapies and dual inhibition in practice
Anti-platelet therapies and dual inhibition in practice Therapeutics; Sept. 25 th 2007 Craig Williams, Pharm.D. Associate Professor of Pharmacy Objectives 1. Understand the pharmacology of thienopyridine
More informationStroke and Headache Headache and Stroke
Stroke and Headache Headache and Stroke Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Tobias Kurth Institute of Public Health Charité Universitätsmedizin Berlin
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationPredictive value of the Essen Stroke Risk Score and Ankle Brachial Index in acute ischaemic stroke patients from 85 German stroke units
Predictive value of the Essen Stroke Risk Score and Ankle Brachial Index in acute ischaemic stroke patients from 85 German stroke units C Weimar, 1 M Goertler, 2 JRöther, 3 E B Ringelstein, 4 H Darius,
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationProf. Jindřich Špinar, MD
Prof. Jindřich Špinar, MD Head of the Internal Cardiology dpt., University Hospital Brno Focuses on clinical cardiology, acute and chronic heart failure, ischemic heart gisease, hypertension Vice head
More informationResults from RE-LY and RELY-ABLE
Results from RE-LY and RELY-ABLE Assessment of the safety and efficacy of dabigatran etexilate (Pradaxa ) in longterm stroke prevention EXECUTIVE SUMMARY Dabigatran etexilate (Pradaxa ) has shown a consistent
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationType of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.
Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis Shah H, Gondek K Record Status
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationThe risk of recurrent stroke is highest immediately after a
Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack Systematic Review and Meta-Analysis of Randomized Controlled Trials Chamila M. Geeganage, PhD; Hans-Christoph
More informationPrevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano
Prevenzione secondaria dell ischemia cerebrale di origine arteriosa Marco Cattaneo Ospedale San Paolo Università degli Studi di Milano Cerebral Ischemia of Arterial Origin (CIAO) Cumulative meta-analysis
More informationPatients who experience a stroke or transient ischemic
REPORTS Therapeutic Interventions for Prevention of Recurrent Ischemic Stroke Howard S. Kirshner, MD Abstract Patients who suffer ischemic stroke or transient ischemic attack (TIA) are at increased risk
More informationSession : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION
Session : Why do stroke patients need a cardiologist? PREVALENCE OF CORONARY ATHEROSCLEROSIS IN PATIENTS WITH CEREBRAL INFARCTION The Asymptomatic Myocardial Ischemia in Stroke and Atherosclerotic Disease
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationCORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS: WHAT CHOICE FOR ANTIPLATELET THERAPY
02_02 03/02/17 14.04 Pagina 9 CORONARY AND PERIPHERAL ARTERY ATHEROSCLEROSIS: WHAT CHOICE FOR ANTIPLATELET THERAPY P. Gresele Department of Medicine, Division of Internal and Cardiovascular Medicine, University
More informationAPPENDIX A NORTH AMERICAN SYMPTOMATIC CAROTID ENDARTERECTOMY TRIAL
APPENDIX A Primary Findings From Selected Recent National Institute of Neurological Disorders and Stroke-Sponsored Clinical Trials That Have shaped Modern Stroke Prevention Philip B. Gorelick 178 NORTH
More informationBayer s Rivaroxaban Demonstrated Superior Protection Against Recurrent Venous Thromboembolism Compared with Aspirin in EINSTEIN CHOICE Study
News Release Not intended for U.S. and UK Media Bayer AG Communications and Public Affairs 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com New Late-Breaking Study Data Presented at ACC.17:
More informationΑντιθρομβωτική αγωγή σε ασθενείς με περιφερική αρτηριακή νόσο των κάτω άκρων
Αντιθρομβωτική αγωγή σε ασθενείς με περιφερική αρτηριακή νόσο των κάτω άκρων Μ. Ματσάγκας, MD, PhD, FEBVS Καθηγητής Αγγειοχειρουργικής Πανεπιστήμιο Θεσσαλίας Prevalence (millions) PAD Affects Millions
More informationSESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationCarlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium
Aspirin in Primary and Secondary Cardiovascular Disease Prevention. Still Four Questions: About Enteric-Coated, Indicated Doses, Use in Diabetes, Use in PVD Carlo Patrono, MD, FESC Catholic University
More informationIdentification of those patients with transient ischemic
Prediction of Recurrent Stroke and Vascular Death in Patients With Transient Ischemic Attack or Nondisabling Stroke A Prospective Comparison of Validated Prognostic Scores Christian Weimar, MD; Jens Benemann,
More informationWhat is the role of dual antiplatelet therapy with clopidogrel and aspirin?
INTERPRETING KEY TRIALS CME CREDIT MIHIR R. BAKHRU, MD Department of Internal Medicine, Cleveland Clinic DEEPAK L. BHATT, MD * Associate Director, Cardiovascular Coordinating Center, Section of Cardiac,
More informationNHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)
Title of Project: NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015) 1 Reason for the review In the UK, low dose aspirin (75mg) is licensed for the prevention of thrombotic
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationBayer Pharma AG Berlin Germany Tel News Release. Not intended for U.S. and UK Media
News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the
More informationLandmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myo
Xarelto (Rivaroxaban) Landmark Phase III Study of Bayer s Xarelto (Rivaroxaban) Initiated for the Secondary Prevention of Myocardial Infarction and Death in Patients with Coronary or Peripheral Artery
More informationCarotid Artery Stenosis
Evidence-Based Approach to Carotid Artery Stenosis Seong-Wook Park, MD Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea Carotid Artery Stenosis Carotid
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationManagement and Investigation of Ischemic Stroke By Etiology
Management and Investigation of Ischemic Stroke By Etiology Andrew M. Demchuk MD FRCPC Director, Calgary Stroke Program Deputy Dept Head, Clinical Neurosciences Heart and Stroke Foundation Chair in Stroke
More informationDisclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.
Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationSecondary Stroke Prevention
Secondary Stroke Prevention Acute stroke conference, Sunnybrook Estates January 20, 2011 Rick Swartz HBSc, MD, PhD, FRCPC Assistant Professor, Department of Medicine, Divisions of Neurology and Obstetrical
More informationFunding Wellcome Trust, the National Institute of Health Research (NIHR) Biomedical Research Centre, Oxford.
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials Peter M Rothwell, Ale Algra, Zhengming
More informationJoshua A. Beckman, MD. Brigham and Women s Hospital
Peripheral Vascular Disease: Overview, Peripheral Arterial Obstructive Disease, Carotid Artery Disease, and Renovascular Disease as a Surrogate for Coronary Artery Disease Joshua A. Beckman, MD Brigham
More informationNew York Cardiovascular Symposium New York, December New York Hilton Midtown
New York Cardiovascular Symposium New York, December 11-13 2015 New York Hilton Midtown Session IV: Trends and Challenges of Prevention December 11 2015 15:15-17:30 Aspirin Therapy in Primary Cardiovascular
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationSlide 1. Slide 2 Conflict of Interest Disclosure. Slide 3 Stroke Facts. The Treatment of Intracranial Stenosis. Disclosure
Slide 1 The Treatment of Intracranial Stenosis Helmi Lutsep, MD Vice Chair and Dixon Term Professor, Department of Neurology, Oregon Health & Science University Chief of Neurology, VA Portland Health Care
More informationSupplementary webappendix
Supplementary webappendix This webappendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Hart RG, Diener H-C, Coutts SB, et al,
More informationClinical Trials. Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany
Clinical Trials Hans-Christoph Diener Senior Professor of Clinical Neuroscienes Medical Faculty University Duisburg-Essen Germany Conflict of Interest Statement German Research Council German Ministry
More informationDownloaded from:
Antithrombotic Trialists Collaboration. (inc. Meade, TW), (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationBayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary and/or peripheral artery disease
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s rivaroxaban submitted to U.S. FDA for approval in patients with coronary
More informationClinical Seminar. Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective
Clinical Seminar Which Diabetic Patient is a Candidate for Percutaneous Coronary Intervention - European Perspective Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationSubscriptions: Information about subscribing to Circulation is online at
Dual Antiplatelet Therapy With Clopidogrel and Aspirin in Symptomatic Carotid Stenosis Evaluated Using Doppler Embolic Signal Detection: The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic
More informationRazionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta
Razionale ed evidenze scientifiche di Doppia Antiaggregazione Piastrinica a lungo termine nel Paziente con Sindrome Coronarica Acuta Giuseppe Musumeci SC Cardiologia Ospedale Santa Croce e Carle Cuneo
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationManagement of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근
Management of Patients with Atrial Fibrillation Undergoing Coronary Artery Stenting 경북대의전원내과조용근 Case (2011, 5) 74-years old gentleman Exertional chest pain Warfarin with good INR control Ex-smoker, social(?)
More informationDisclosures. An Update on TIA and Minor Stroke. The Agenda PROGNOSIS PATHOPHYSIOLOGY GUIDELINES AND PROVEN MANAGEMENT STRATEGIES AGGRESSIVE TREATMENT
Disclosures An Update on TIA and Minor Stroke Dr. Johnston is principal investigator for the POINT trial, sponsored by the NIH but with drug and placebo contributed by Sanofi-Aventis. S. Claiborne Johnston,
More informationThe American Heart Association/American Stroke Association
AHA/ASA Science Advisory Update to the AHA/ASA Recommendations for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack Robert J. Adams, MS, MD, FAHA, Chair; Greg Albers, MD;
More informationCritical Review Form Therapy
Critical Review Form Therapy A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects, Lancet-Neurology 2007; 6: 953-960 Objectives: To evaluate the effect of
More informationPeripheral Artery Disease Role of Exercise, Endovascular and Surgical Options
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options Jeffrey W. Olin, D.O., F.A.C.C., F.A.H.A. Professor of Medicine (Cardiology) Director of Vascular Medicine & the Vascular Diagnostic
More informationMedical Therapy for Peripheral Artery Disease
Medical Therapy for Peripheral Artery Disease Beau M. Hawkins, MD, FSCAI University of Oklahoma Health Sciences Center, Oklahoma City, OK Sahil A. Parikh, MD, FSCAI Columbia University Medical Center,
More informationReview Article Stroke Prevention: Managing Modifiable Risk Factors
Stroke Research and Treatment Volume 2012, Article ID 391538, 15 pages doi:10.1155/2012/391538 Review Article Stroke Prevention: Managing Modifiable Risk Factors Silvia Di Legge, 1 Giacomo Koch, 1, 2 Marina
More informationThe Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study
The Japan Statin Treatment Against Recurrent Stroke (J-STARS): a multicenter, randomized, open-label, parallel-group study Masayasu Matsumoto 1, Naohisa Hosomi 1, Yoji Nagai 2, Tatsuo Kohriyama 3, Shiro
More informationDEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE. Matthew Starr, MD Stroke Attending
DEBATE: PFO MANAGEMENT TO CLOSE OR NOT TO CLOSE Matthew Starr, MD Stroke Attending DISCLOSURES None DEBATE Should PFO be closed? * * Sometimes yes THE CASE AGAINST PFO CLOSURE 1. Did the PFO cause the
More informationLuisa Vinciguerra. Ictus recidivanti
Luisa Vinciguerra Ictus recidivanti Recurrent Strokes DEFINITION Population-based studies exclude strokes: - within 28 or 21 days of the incident event - events in the same vascular territory as the original
More informationLiping Liu Dpet. of Neurology and Stroke Center Beijing Tiantan Hospital Capital Medical University
Liping Liu Dpet. of Neurology and Stroke Center Beijing Tiantan Hospital Capital Medical University Disclosures Conflict of interest disclosures: No Disclosures Funding The CHANCE trial is funded by the
More informationNon-commercial use only
Italian Journal of Medicine 2016; volume 10:202-206 Embolic stroke of undetermined source: a retrospective analysis from an Italian Stroke Unit Marco Masina, 1 Annalena Cicognani, 1 Carla Lofiego, 2 Simona
More information